Cited by 4,262Protein Degradation and InhibitorsChromatin Remodeling and CancerEpigenetics and DNA Methylation

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Selective inhibition of BET bromodomains

Open access

Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B., Fedorov, Oleg, Morse, Elizabeth M., Keates, Tracey, Hickman, Tyler T., Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R., Wang, Yuchuan, Christie, Amanda L., West, Nathan, Cameron, Michael J., Schwartz, Brian, Heightman, Tom D., La Thangue, Nicholas, French, Christopher A., Wiest, Olaf, Kung, Andrew L., Knapp, Stefan, Bradner, James E.·2010·Nature

DOI 10.1038/nature09504PMC PMC3010259

Open this paper in CoChat — free account

Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09504

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 273
Retracted
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Sueoka, H., Komatsu, H., Kobayashi, H. & Ehara, S. Thienotriazolodiazepine Compounds and Medicinal Uses Thereof 1–50 (Yoshitomi Pharmaceutical Industries, Ltd, 1998)

Sorted by citations

Items 1,001–1,029 of 1,029

Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules
Daguer, J., Zambaldo, C., Abegg, D., Barluenga, S., Tallant, C., Müller, S., Adibekian, A., & Winssinger, N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412276 · Cited by 65
p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer
Xu, S., Fan, L., Jeon, H.-Y., Zhang, F., Cui, X., Mickle, M. B., Peng, G., Hussain, A., Fazli, L., Gleave, M. E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0233 · Cited by 64
Self-citation
Importance of Three-Body Problems and Protein–Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations
Li, W., Zhang, J., Guo, L., & Wang, Q. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01150 · Cited by 63
Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1
Fahey, J. M., Stancill, J. S., Smith, B. C., & Girotti, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000443 · Cited by 59
BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes
Padmanabhan, A., Alexanian, M., Linares-Saldana, R., González-Terán, B., Andreoletti, G., Huang, Y., Connolly, A. J., Kim, W., Hsu, A., Duan, Q., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047753 · Cited by 60
Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen–Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design
Eron, S. J., Huang, H., Agafonov, R. V., Fitzgerald, M. E., Patel, J., Michael, R. E., Lee, T. D., Hart, A. A., Shaulsky, J., Nasveschuk, C. G., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00376 · Cited by 57
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
Wang, H., Teriete, P., Hu, A., Raveendra-Panickar, D., Pendelton, K., Lazo, J. S., Eiseman, J., Holien, T., Misund, K., Oliynyk, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6116 · Cited by 53
A computational method for detection of ligand-binding proteins from dose range thermal proteome profiles
Kurzawa, N., Becher, I., Sridharan, S., Franken, H., Mateus, A., Anders, S., Bantscheff, M., Huber, W., & Savitski, M. M. (2020) · Nature Communications · doi:10.1038/s41467-020-19529-8 · Cited by 53
Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
Jiang, F., Wei, Q., Li, H., Li, H., Cui, Y., Ma, Y., Chen, H., Cao, P., Lu, T., & Chen, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115181 · Cited by 48
Vitamin C Sensitizes Melanoma to BET Inhibitors
Mustafi, S., Camarena, V., Volmar, C.-H., Huff, T. C., Sant, D. W., Brothers, S. P., Liu, Z.-J., Wahlestedt, C., & Wang, G. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2040 · Cited by 47
“BET proteins, such as BRD4, contain two bromodomains (BD1 and BD2), which are druggable targets (7, 8).”
Background
Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
Larue, R. C., Plumb, M. R., Crowe, B. L., Shkriabai, N., Sharma, A., DiFiore, J., Malani, N., Aiyer, S. S., Roth, M. J., Bushman, F. D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku135 · Cited by 44
BRD4 inhibitors block telomere elongation
Wang, S., Pike, A. M., Lee, S. S., Strong, M. A., Connelly, C. J., & Greider, C. W. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx561 · Cited by 45
A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader
Payne, N. C., Maksoud, S., Tannous, B. A., & Mazitschek, R. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.05.003 · Cited by 44
BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy
Antolic, A., Wakimoto, H., Jiao, Z., Gorham, J. M., DePalma, S. R., Lemieux, M. E., Conner, D. A., Lee, D. Y., Qi, J., Seidman, J. G., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138687 · Cited by 41
Self-citation
Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation
Carey, H. A., Hildreth, B. E., Geisler, J. A., Nickel, M. C., Cabrera, J., Ghosh, S., Jiang, Y., Yan, J., Lee, J., Makam, S., et al. (2018) · Bone Research · doi:10.1038/s41413-018-0011-1 · Cited by 40
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Protein–Protein Interaction Modulators for Epigenetic Therapies
(2018) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2017.06.002 · Cited by 31
Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
PTEN in Regulating Hematopoiesis and Leukemogenesis
Wu, Y., Zhu, H., & Wu, H. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036244 · Cited by 22
A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes
Pinch, B. J., Buckley, D. L., Gleim, S., Brittain, S. M., Tandeske, L., D'Alessandro, P. L., Hauseman, Z. J., Lipps, J., Xu, L., Harvey, E. P., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.08.007 · Cited by 20
The role of enhancer RNAs in epigenetic regulation of gene expression
Rahnamoun, H., Orozco, P., & Lauberth, S. M. (2020) · Transcription · doi:10.1080/21541264.2019.1698934 · Cited by 16
Virus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation
Wang, S., Song, Y., Wang, Y., Gao, Y., Yu, S., Zhao, Q., Jin, X., & Lu, H. (2018) · Chemical Research in Chinese Universities · doi:10.1007/s40242-018-7272-5 · Cited by 6
Self-citation
Senescence Can Be BETter without the SASP?
Vizioli, M. G., & Adams, P. D. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0485 · Cited by 6
Targeting transcription factors through an IMiD independent zinc finger domain
Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00241-3 · Cited by 8
Self-citation

Authors: Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., & Bradner, J. E.
Affiliations: University of Oxford (GB)
Harvard University (US)
University of Notre Dame (US)
Brigham and Women's Hospital (US)
Boston Children's Hospital (US)
Corresponding author: Knapp, Stefan
Bradner, James E.
ORCID: Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Fedorov, Oleg
Hickman, Tyler T.
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Schwartz, Brian
Heightman, Tom D.
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-09-24
Volume: 468
Issue: 7327
Pages: 1067-1073
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09504
PMC: PMC3010259
OpenAlex: W2041535798
Cited by: 4,262
References: 42
Citations by year: 2026: 217 · 2025: 307 · 2024: 304 · 2023: 307 · 2022: 309 · 2021: 323 · 2020: 340 · 2019: 323 · 2018: 303 · 2017: 306 · 2016: 334 · 2015: 279 · 2014: 246 · 2013: 177 · 2012: 117
FWCI: 48.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders: Wellcome Trust
Cancer Research UK (13058)
U.S. Public Health Service (T32-075762)
Canadian Institutes of Health Research
National Cancer Institute (K08CA128972)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: BET inhibitors, JQ1, BRD4, epigenetic reader protein, protein-protein interaction inhibition, squamous cell carcinoma, histone acetylation, co-crystal structure, chemical probes, transcriptional regulation
MeSH terms: Bromodomain Containing Proteins, Amino Acid Sequence, Animals, Azirines, Binding Sites, Carcinoma, Squamous Cell, Cell Differentiation, Chromatin, Dihydropyridines, Female, Humans, Mice, Nude, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Recombinant Proteins, Skin Neoplasms, Stereoisomerism, Transcription Factors, Sequence Alignment, Protein Structure, Tertiary, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective inhibition of BET bromodomains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks